Back

A multi-agent workflow converts CAR-T patient evidence into experimentally testable hypotheses

Wang, S.; Li, Y.-R.; Wang, Q.; Yang, Y.; Shen, X.; Li, H.; Nan, H.; Chen, Z.; Zhu, Y.; Zhang, B.; Ding, H.; Soto, J.; Park, S.; Zheng, Y.; Huang, X.; Yang, L.; Li, D.; Li, S.

2026-07-16 bioengineering
10.64898/2026.07.15.738646 bioRxiv
Show abstract

The rapid expansion of chimeric antigen receptor (CAR) T cell studies has produced a fragmented evidence landscape linking publications, repository accessions, patient metadata and mechanistic observations. Here we present BioPathfinder, a multi-agent discovery engine for CAR-T research evidence construction, hypothesis generation and validation planning. Unlike existing LLM-based and agentic approaches centered on predefined CAR-T development tasks, BioPathfinder constructs a provenance-tracked resource linking scRNA-seq datasets from treated patients to their publications and uses it to generate diverse, falsifiable and dataset-aware mechanistic hypotheses prioritized for computational and experimental validation by role-specialized LLM reviewer subagents. Applied to the curated CAR-T-treated patient paper-dataset corpus, BioPathfinder nominated candidate mechanisms of CAR-T persistence, dysfunction and therapeutic resistance, including the hypothesis that genes associated with an NK-like transition program could be targeted to reduce CAR-T exhaustion and promote persistence. Patient scRNA-seq analysis showed that this NK-like transition-associated program was enriched in exhausted post-infusion CAR-T cell states. Virtual perturbation further prioritized transition-associated KLR-family receptor genes, including KLRC1, KLRD1 and KLRG1. Expert review selected KLRC1, encoding NKG2A, for experimental testing. In vitro and in vivo chronic-stimulation models showed that NKG2A marked CD8+ CAR-T cells with activated and exhaustion-associated phenotypes. NKG2A blockade improved antitumour function and persistence-associated readouts in vivo. These results show that structured clinical single-cell evidence can be transformed by domain-specialized multi-agent systems into experimentally actionable CAR-T engineering hypotheses. HighlightsO_LIBioPathfinder structures fragmented CAR-T patient evidence into a provenance-tracked paper-dataset resource. C_LIO_LIMulti-agent planning and review prioritize experimentally testable mechanisms of CAR-T dysfunction. C_LIO_LIExpert selection from BioPathfinder-nominated NK-like transition-associated genes identifies KLRC1/NKG2A blockade as a strategy to promote CAR-T persistence. C_LI

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.